Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection

被引:177
作者
Brenner, BG
Routy, JP
Petrella, M
Moisi, D
Oliveira, M
Detorio, M
Spira, B
Essabag, V
Conway, B
Lalonde, R
Sekaly, RP
Wainberg, MA
机构
[1] McGill Univ, Jewish Gen Hosp, Lady Davis Inst, AIDS Ctr, Montreal, PQ H3T 1E2, Canada
[2] McGill Univ, Ctr Hlth, Montreal, PQ H3T 1E2, Canada
[3] Univ Montreal, Montreal, PQ, Canada
[4] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
关键词
D O I
10.1128/JVI.76.4.1753-1761.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
This study examines the persistence and fitness of multidrug-resistant (MDR) viruses acquired during primary human immunodeficiency virus infection (PHI). In four individuals, MDR infections persisted over the entire study period, ranging from 36 weeks to 5 years, in the absence of antiretroviral therapy. In stark contrast, identified source partners in two cases showed expected outgrowth of wild-type (WT) virus within 12 weeks of treatment interruption. In the first PHI case, triple-class MDR resulted in low plasma viremia (1.6 to 3 log copies/ml) over time compared with mean values obtained for an untreated PHI group harboring WT infections (4.1 to 4.3 log copies/ml). Increasing viremia in PHI patient 1 at week 52 was associated with the de novo emergence of a protease inhibitor-resistant variant through a recombination event involving the original MDR virus. MDR infections in two other untreated PHI patients yielded viremia levels typical of the untreated WT group. A fourth patient's MDR infection yielded low viremia (<50 to 500 copies/ml) for 5 years despite his having phenotypic resistance to all antiretroviral drugs in his treatment regimen. In two of these PHI cases, a rebound to higher levels of plasma viremia only occurred when the M184V mutation in reverse transcriptase could no longer be detected and, in a third case, nondetection of M184V was associated with an inability to isolate virus. To further evaluate the fitness of MDR variants acquired in PHI, MDR and corresponding WT viruses were isolated from index and source partners, respectively. Although MDR viral infectivity (50% tissue culture infective dose) was comparable to that observed for WT viruses, MDR infections in each case demonstrated 2-fold and 13- to 23-fold reductions in p24 antigen and reverse transcriptase enzymatic activity, respectively. In dual-infection competition assays, MDR viruses consistently demonstrated a marked replicative disadvantage compared with WT virus. These results indicate that MDR viruses that are generated following PHI can establish persistent infections as dominant quasispecies despite their impaired replicative competence.
引用
收藏
页码:1753 / 1761
页数:9
相关论文
共 34 条
  • [1] Batisse D., 1998, AIDS (London), V12, P824
  • [2] A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
    Baxter, JD
    Mayers, DL
    Wentworth, DN
    Neaton, JD
    Hoover, ML
    Winters, MA
    Mannheimer, SB
    Thompson, MA
    Abrams, DI
    Brizz, BJ
    Ioannidis, JPA
    Merigan, TC
    [J]. AIDS, 2000, 14 (09) : F83 - F93
  • [3] HIV-1 drug resistance in newly infected individuals
    Boden, D
    Hurley, A
    Zhang, LQ
    Cao, YZ
    Guo, Y
    Jones, E
    Tsay, J
    Ip, J
    Farthing, C
    Limoli, K
    Parkin, N
    Markowitz, M
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (12): : 1135 - 1141
  • [4] BRENNER BG, 1993, CLIN EXP IMMUNOL, V93, P142
  • [5] Clevenbergh P, 2000, ANTIVIR THER, V5, P65
  • [6] HIV POPULATION-DYNAMICS IN-VIVO - IMPLICATIONS FOR GENETIC-VARIATION, PATHOGENESIS, AND THERAPY
    COFFIN, JM
    [J]. SCIENCE, 1995, 267 (5197) : 483 - 489
  • [7] Selective vertical transmission of HIV-1 antiretroviral resistance mutations
    Colgrove, RC
    Pitt, J
    Chung, PH
    Welles, SL
    Japour, AJ
    [J]. AIDS, 1998, 12 (17) : 2281 - 2288
  • [8] Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.
    Deeks, SG
    Wrin, T
    Liegler, T
    Hoh, R
    Hayden, M
    Barbour, JD
    Hellmann, NS
    Petropoulos, CJ
    McCune, JM
    Hellerstein, MK
    Grant, RM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (07) : 472 - 480
  • [9] Devereux HL, 1999, AIDS, V13, pF123, DOI 10.1097/00002030-199912240-00001
  • [10] Perinatal transmission of major, minor, and multiple maternal human immunodeficiency virus type 1 variants in utero and intrapartum
    Dickover, RE
    Garratty, EM
    Plaeger, S
    Bryson, YJ
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (05) : 2194 - 2203